- Raised $22M funding round led by Pontifax, Dec 2019
- Raised $4.5M funding round, Feb 2016
- Raised $600k funding round, Dec 2014
About
Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug for targeted fat reduction. The company has developed a new chemical entity that converts white adipose tissue (WAT) into brown adipose tissue (BAT) after a single injection into subcutaneous fat, potentially providing a new way to treat people who are overweight or obese. Raziels primary drug candidate is RZL-012, an injectable drug that is currently in preclinical development. RZL-012 is administered by several injections delivered in a single injection session. Once injected, RZL-012 triggers immediate fat-cell death, followed by a transient inflammatory process that lasts about a month during which necrotic fat tissue is replaced by fibrotic tissue. This results in a significant long-term, sustained shrinkage of fat tissue. The companys products are based on work by the team led by Professor Muli Ben-Sasson, who discovered a family of compounds that are able to influence the fate of fat-tissue cells (adipocytes) and convert them from WAT to BAT tissues. In November 2019, Raziel received FDA approval to develop RZL-012 as an orphan drug for Dercums disease.
Funding history · 5 rounds · $27.1M total
Q&A
- What is Raziel Therapeutics' primary drug candidate?
- Raziel Therapeutics' primary drug candidate is RZL-012, an injectable drug currently in preclinical development for targeted fat reduction.
- What is the mechanism of action for Raziel Therapeutics' RZL-012?
- RZL-012 triggers immediate fat-cell death, followed by a transient inflammatory process where necrotic fat tissue is replaced by fibrotic tissue, resulting in significant long-term fat tissue shrinkage.
- When was Raziel Therapeutics founded?
- Raziel Therapeutics was founded in August 2012.
- How many employees does Raziel Therapeutics currently have?
- Raziel Therapeutics has 1-10 employees.
- What was the total amount raised by Raziel Therapeutics to date?
- Raziel Therapeutics has raised a total of $27,100,000 USD.
- Which investors participated in Raziel Therapeutics' December 2019 funding round?
- The December 2019 funding round for Raziel Therapeutics included Pontifax.
- What is the current stage of Raziel Therapeutics' funding?
- Raziel Therapeutics is currently in its Series C funding stage.
- When did Raziel Therapeutics receive FDA approval for RZL-012 as an orphan drug?
- In November 2019, Raziel Therapeutics received FDA approval to develop RZL-012 as an orphan drug for Dercum's disease.
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | raziel-therapy.com |
|---|
Identifiers & details
| Founded | 2012-8 |
|---|---|
| Employees (exact) | 6 |
Radar intelligence
Patents
| EPO | 9 |
|---|
Web history (Wayback)
| Domain | raziel-therapy.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|